CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques. It has potential applications in various inflammatory conditions such as cystic...
- Mechanism
- Curator reviewed · 1 reference
CSL324 binds to G-CSFR, which has been shown to neutralize the activity of G-CSF. Thus, this antibody is hypothesized to reduce G-CSF-driven mobilization and recruitment, which then, in turn, will aid in inflammation reduction. CSL324 also inhibits the G-CSF-mediated expression of CXCR1 and CXCR2 on neutrophils. Currently, it is being investigated against inflammation and COVID-19.
- Code names
- CSL324
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Anumigilimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account